• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Gout News / Optimal Colchicine Dosage for Acute Gout Explored

Optimal Colchicine Dosage for Acute Gout Explored

April 15, 2010 By Arthritis Center

Gout
Gout

Despite being used for decades as a primary treatment for acute gout, optimal colchicine dosing has not been systematically evaluated.  This is potentially important, as higher doses of colchicine can frequently be associated with the undesired consequence of severe diarrhea and gastrointestinal distress.  Here, Terkeltaub et al (Arthritis Rheum 2010; 62(4): 1060) explore different dosing strategies for colchicine in the first randomized, blinded, placebo controlled trial, named AGREE (Acute Gout Flare Receiving Colchicine Evaluation)

Methods

Adult men and postmenopausal women with confirmed gout and a history of frequent flares were randomized to one of three treatment groups:

  1. low dose colchicine- 1.2 mg followed by 0.6 mg in one hour (followed by placebo doses on subsequent hours): total dose=1.8 mg
  2. high dose colchicine – 1.2 mg followed by 0.6 mg per hour for 5 hours: total dose 4.8 mg
  3. all placebo

Participants were enrolled at 54 centers in the U.S. in 2007-2008.  Patients used supplied study medications within 12 hours of the onset of flare symptoms, with symptoms monitored in a diary.  Post-flare study visits were planned for within 48 hours of flare onset.  The primary endpoint was the proportion of patients with a 50% or greater reduction in pain within 24 hours of study drug.

Results

Among the 575 randomized patients, 185 had a gout flare and used the study medication.  There were 52 (28%) in the high dose group, 74 (40%) in the low dose group, and 59 (32%) in the placebo group.  Mean age was 52 years, with the majority of participants being male (95%), Caucasian (83%), with longstanding gout.  Tophi were uncommon (9%).  Despite a mean serum urate concentration of 8.8 mg/dl, less than a third were receiving urate lowering therapy.

Table. Efficacy Outcomes According to Treatment Allocation

High Dose
(n=52)

Low Dose
(n=74)

Placebo
(n=58)

p-value high dose vs. placebo

p-value
low dose vs. placebo

 50% reduction in pain at 24 hours

33%

38%

16%

0.034

0.005

≥ 50% reduction in pain at 32 hours

37%

42%

17%

0.022

0.002

≥ 2 unit reduction in pain at 24 hours

35%

43%

17%

0.037

0.002

≥ 2 unit reduction in pain at 32 hours

39%

46%

17%

0.012

0.001

Rescue medications were used significantly less frequently in the colchicine groups, and did not differ by low-dose vs. high-dose allocation.

For safety, there were no serious adverse events.  Diarrhea was observed in 77% of high dose colchicine treated patients compared to 23% of low-dose and 14% of placebo treated patients.  Severe diarrhea was observed in 19% of high dose patients, compared to none in the other groups.  Vomiting was only observed in the high dose colchicine group.  These differences were all statistically significant.

Conclusions

Low dose colchicine was as efficacious as high dose in relieving the pain of recurrent gout flares with a more favorable side effect profile.

Editorial Comment

Colchicine has been widely used to treat acute gout for decades, yet its usage has been based primarily on style than hard data.  This study definitively supports the use of this low dose regimen over higher doses.  Even with higher doses, more than 60% of patients did not have at least a 50% reduction in the their symptoms in the first 24-32 hours.  This suggests that chronic urate lowering, rather than flare management, should be the focus of care in patients with frequent attacks, a modality that was absent in many of these patients.  Whether other treatments for acute gout (i.e. NSAIDs or glucocorticoids) are superior to this regimen has not been studied.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy